Monoclonal antibody cocktail neutralises Delta variant: Study | Hyderabad News – Times of India

HYDERABAD: In what is the first study globally to test the effectiveness of the monoclonal antibody (mAb) cocktail against the dreaded Delta variant, Hyderabad-based AIG Hospitals along with the Asian Healthcare Foundation, CCMB Hyderabad and Institute of Life Sciences, found that the therapy is able to neutralize the Delta variant and reduces by 100% severe disease and death in Delta infected high-risk individuals.
The study titled ‘Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study’, which has been published in peer-reviewed Journal of Internal Medicine, found that high risk patients, infected with the Delta variant, that were treated with the mAb cocktail, which was rolled out by Roche earlier this year, also showed faster resolution of symptoms.
Elaborating on the findings, AIG Hospitals chairman Dr D Nageshwar Reddy said that 75% of the patients that received the mAb therapy became RT-PCR negative by Day 7 and 78% of patients got relieved of their clinical symptoms like fever and cough by Day 7. Also, he said, none of the participants developed severe disease or died, there was no increase in inflammatory markers (that cause severe disease) and on follow-up none of the patients reported any post-Covid syndrome.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *